Vedanta unveils state-of-the-art manufacturing facility to provide clinical and commercial supply of oral therapies based on defined bacterial consortia

Cambridge, mass.--(business wire)--vedanta biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned phase 3 study and potential commercial launch of its lead candidate, ve303, in clostridioides difficile infection. the large-scale current good manufacturing p
PRTC Ratings Summary
PRTC Quant Ranking